The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 28, 2017
Filed:
Oct. 25, 2015
Ming-hsin LI, Taoyuan, TW;
Chyng-yann Shiue, Taoyuan, TW;
Han-chih Chang, Taoyuan, TW;
Han-hsiang Chu, Taoyuan, TW;
Ming-Hsin Li, Taoyuan, TW;
Chyng-Yann Shiue, Taoyuan, TW;
Han-Chih Chang, Taoyuan, TW;
Han-Hsiang Chu, Taoyuan, TW;
INSTITUTE OF NUCLEAR ENERGY RESEARCH, Longtan, Taoyuan, TW;
Abstract
A method of synthesizing a compound of imaging agent with HDAC (histone deacetylase) inhibitor consists of two parts, the first part of the method is to provide the inhibitor of HDAC with a compound of imaging agent that includes HDAC inhibitor BNL-26 (CHNO) and its analogs to be labeled with radionuclide F-18, producing a series of new nuclear medicine tracers: BNL-26-CHCH18F, BNL-26a-CHCH18FF, BNL-26b-CHCH18F, BNL-26c-CHCH18F and BNL-26d-CHCH18F. These nuclear medicine with imaging agents can be used as a tracer in vivo binding to over-expression HDAC and produce a HDAC nuclear medicine imaging effect to serve for clinical diagnosis. The second part of the method is to provide a slightly adjusted a structural framework of BNL-26 and use pyridine to substitute the benzene ring of the BNL-26 structure, and then synthesize with other substituent to produce a series of additional 30 more HDAC inhibitors, named from Iner-1 to Iner-30 compounds.